There are described compounds of formula (I): (I) and their use as a medicament in the treatment of diseases associated with the abnormal or elevated catabolism of tryptophan, such as, cancer, immunosuppression, viral infection, depression, a neurodegenerative disorder, trauma, age-related cataracts, organ transplant rejection, or an autoimmune disorder in a patient.

##STR00001##

There are described compounds of formula (I): (I) and their use as a medicament in the treatment of diseases associated with the abnormal or elevated catabolism of tryptophan, such as, cancer, immunosuppression, viral infection, depression, a neurodegenerative disorder, trauma, age-related cataracts, organ transplant rejection, or an autoimmune disorder in a patient.

##STR00001##

This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.

This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.

A compound of formula (I) or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer for use in the treatment or prophylaxis of brain ischemia, ischemic brain injury, Ischemic Stroke (IS), haemorrhagic stroke, traumatic brain injury, spinal cord injury.

##STR00001##

A compound of formula (I) or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer for use in the treatment or prophylaxis of brain ischemia, ischemic brain injury, Ischemic Stroke (IS), haemorrhagic stroke, traumatic brain injury, spinal cord injury.

##STR00001##

The present invention relates to a process for preparing compounds of the formula (I)

##STR00001##

by halogenating compounds of the formula (II),

##STR00002##

where in R.sup.1, R.sup.2, R.sup.3 and X are defined according to the invention.

The present invention relates to a process for preparing compounds of the formula (I)

##STR00001##

by halogenating compounds of the formula (II),

##STR00002##

where in R.sup.1, R.sup.2, R.sup.3 and X are defined according to the invention.

A process for the sigmatropic rearrangement of the compound of formula

##STR00001##

in which R.sub.3 is an NO.sub.2 group and R.sub.4 is either a hydrogen or an NO.sub.2 group, includes heat treating the compound by microwave.

A process for the sigmatropic rearrangement of the compound of formula

##STR00001##

in which R.sub.3 is an NO.sub.2 group and R.sub.4 is either a hydrogen or an NO.sub.2 group, includes heat treating the compound by microwave.